XML 59 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Fair value of financial instruments and marketable securities - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jan. 31, 2020
Sep. 30, 2020
Sep. 30, 2019
Jun. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Jun. 29, 2020
Apr. 29, 2020
Dec. 31, 2019
May 31, 2019
Aug. 31, 2015
Financial assets and liabilities measured at fair value on recurring basis                      
Write downs of available for sale debt securities   $ 0     $ 0            
Realized gain (loss) from sale of marketable securities   300,000     500,000            
Increase in allowance for credit losses   0     0            
Deferred consideration payable   0     0       $ 40,000,000    
Unrealized gain (loss) on equity investment         852,000 $ 2,529,000          
Investment In MRI   $ 7,000,000.0     7,000,000.0            
Purchase of convertible debt investment $ 10,000,000.0       $ 10,000,000 0          
Conversion price per share (in dollars per share)   $ 6.00     $ 6.00            
Debt instrument, convertible, period         5 years            
Marketable securities   $ 707,049,000     $ 707,049,000       398,535,000    
Transfers of assets measured between Level 1, Level 2, and Level 3   0     0       0    
Non-cash stock consideration, acquisition         42,869,000 0          
Operating Expenses   173,535,000 $ 131,891,000   597,296,000 378,895,000          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset   (8,400,000) $ (9,500,000)   (16,980,000) $ (35,960,000)          
Debt Securities, Available-for-sale, Unrealized Gain   1,400,000     $ 600,000            
Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Issuance of common stock related to rights exchange (in shares)         2,821,176            
SARs                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   0     $ 0            
3.00% Convertible senior notes due 2022 | Convertible debt                      
Financial assets and liabilities measured at fair value on recurring basis                      
Principal   150,000,000     150,000,000       150,000,000   $ 150,000,000.0
Interest rate ( as a percent )                     3.00%
Fair value of convertible notes   171,300,000     171,300,000       171,200,000    
Conversion price per share (in dollars per share)                     $ 56.34
1.50% Convertible senior notes due 2026 | Convertible debt                      
Financial assets and liabilities measured at fair value on recurring basis                      
Principal   $ 287,500,000     $ 287,500,000       $ 287,500,000    
Interest rate ( as a percent )   1.50%     1.50%       1.50%    
Fair value of convertible notes   $ 329,200,000     $ 329,200,000       $ 335,000,000.0    
Conversion price per share (in dollars per share)   $ 52.52     $ 52.52            
Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Development milestone payments which the entity is obligated to pay   $ 40,000,000.0     $ 40,000,000.0     $ 40,000,000.0      
Net sales amount               $ 150,000,000.0      
Deferred consideration payable   0     0            
Non-cash stock consideration, acquisition   36,900,000                  
Milestone Payment Obligations             $ 174,000,000.0        
Gain Of Settlement, Development Milestones   700,000                  
Loss Of Settlement, Regulatory Milestones   11,300,000                  
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset   1,000,000.0                  
Contingent Consideration, Transaction Fees   $ 2,000,000.0     $ 2,000,000.0            
Agilis | Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Issuance of common stock related to rights exchange (in shares)       2,821,176              
Agilis | Minimum                      
Financial assets and liabilities measured at fair value on recurring basis                      
Product sales   2.00%     2.00%     2.00%      
Development milestone payments which the entity is obligated to pay             37,600,000 $ 37,600,000      
Agilis | Maximum                      
Financial assets and liabilities measured at fair value on recurring basis                      
Product sales   6.00%     6.00%     6.00%      
Development milestone payments which the entity is obligated to pay   $ 60,000,000.0     $ 60,000,000.0   $ 40,000,000.0        
Priority review voucher amount         535,000,000.0            
Net sales amount   150,000,000.0     150,000,000.0            
Non-collaborative Arrangement Transactions | Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Development milestone payments which the entity is obligated to pay   40,000,000.0     40,000,000.0            
Recurring basis | Total                      
Financial assets and liabilities measured at fair value on recurring basis                      
Estimated fair value of deferred consideration payable   2,400,000     2,400,000       40,000,000    
Liability value   95,900,000     95,900,000       65,800,000    
Common stock                      
Financial assets and liabilities measured at fair value on recurring basis                      
Shares owned                   $ 4,000,000.0  
Fair value of shares (in dollars per share)                   $ 3.10  
Unrealized gain (loss) on equity investment   2,500,000     900,000            
Deferred consideration payable | Recurring basis | Total                      
Financial assets and liabilities measured at fair value on recurring basis                      
Marketable securities   $ 10,633,000     $ 10,633,000            
Development and Regulatory Milestone | Probability of Success | Weighted Average | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   42     42            
Development and Regulatory Milestone | Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   $ 138,200,000     $ 138,200,000       $ 290,500,000    
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Minimum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.031     0.031       0.022    
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Maximum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.053     0.053       0.047    
Development and Regulatory Milestone | Agilis | Measurement Input, Discount Rate | Weighted Average | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   4.2     4.2            
Development and Regulatory Milestone | Agilis | Probability of Success | Minimum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.25     0.25       0.25    
Development and Regulatory Milestone | Agilis | Probability of Success | Maximum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.94     0.94       0.94    
Liability, Net Sales Milestones and Royalties | Probability of Success | Weighted Average | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   48     48            
Liability, Net Sales Milestones and Royalties | Agilis                      
Financial assets and liabilities measured at fair value on recurring basis                      
Liability value   $ 95,900,000     $ 95,900,000       $ 65,800,000    
Liability, Net Sales Milestones and Royalties | Agilis | Measurement Input, Discount Rate | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.120     0.120       0.145    
Liability, Net Sales Milestones and Royalties | Agilis | Probability of Success | Minimum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.25     0.25       0.25    
Liability, Net Sales Milestones and Royalties | Agilis | Probability of Success | Maximum | Commitments                      
Financial assets and liabilities measured at fair value on recurring basis                      
Rights Exchange settlement   0.94     0.94       0.89